The supplier must be able to provide all of these items on request:
- Standard Written Order (SWO)
- Beneficiary Authorization
- Proof of Delivery (POD)
- Continued Need
- Continued Use
- Medical records from treating practitioner as noted below

Medical Records should contain:

Small Volume Nebulizers (A7003, A7004, A7005), Related Compressor (E0570), and FDA-Approved Inhalation Drugs

- Medical records support the medical necessity to administer one (1) of the following inhalation drugs for one (1) of the listed conditions:

<table>
<thead>
<tr>
<th>Drug</th>
<th>HCPCS</th>
<th>Covered Condition (see LCD for ICD Code)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albuterol</td>
<td>J7611, J7613</td>
<td>Obstructive pulmonary disease</td>
</tr>
<tr>
<td>Arformoterol</td>
<td>J7605</td>
<td>Obstructive pulmonary disease</td>
</tr>
<tr>
<td>Budesonide</td>
<td>J7626</td>
<td>Obstructive pulmonary disease</td>
</tr>
<tr>
<td>Cromolyn</td>
<td>J7631</td>
<td>Obstructive pulmonary disease</td>
</tr>
<tr>
<td>Formoterol</td>
<td>J7606</td>
<td>Obstructive pulmonary disease</td>
</tr>
<tr>
<td>Ipratropium</td>
<td>J7644</td>
<td>Obstructive pulmonary disease</td>
</tr>
<tr>
<td>Levalbuterol</td>
<td>J7612, J7614</td>
<td>Obstructive pulmonary disease</td>
</tr>
<tr>
<td>Metaproterenol</td>
<td>J7669</td>
<td>Obstructive pulmonary disease</td>
</tr>
<tr>
<td>Dornase Alpha</td>
<td>J7639</td>
<td>Cystic fibrosis</td>
</tr>
<tr>
<td>Tobramycin</td>
<td>J7682</td>
<td>Cystic fibrosis or Bronchiectasis</td>
</tr>
<tr>
<td>Pentamidine</td>
<td>J2545</td>
<td>Human Immunodeficiency Virus (HIV), Pneumocystosis or complications of organ transplant</td>
</tr>
<tr>
<td>Acetylcysteine</td>
<td>J7608</td>
<td>Persistent thick or tenacious pulmonary secretions</td>
</tr>
</tbody>
</table>

The content of this document was prepared as an educational tool and is not intended to grant rights or impose obligations. Use of this document is not intended to take the place of either written law or regulations. Suppliers are reminded to review the Local Coverage Determination and Policy Article for specific documentation guidelines.
Large Volume Nebulizer (A7007, A7017), Related Compressor (E0565, E0572), and Water or Saline (A4217, A7018). Combination code E0585 covered for the same indications.

- Medical records support the medical necessity to deliver humidity to beneficiary with thick, tenacious secretions due to (See LCD for ICD codes):
  - Cystic fibrosis
  - Bronchiectasis
  - Tracheostomy
  - Tracheobronchial Stent

Filtered Nebulizer (A7006) and Compressor (E0565, E0572)

- Medical records support the medical necessity to deliver pentamidine (J2545) to beneficiaries with (see LCD for ICD codes):
  - HIV
  - Pneumocystosis
  - Complications of organ transplant

Small Volume Ultrasonic Nebulizer (E0574) and Treprostinil (J7686) or Controlled Dose Inhalation Drug Delivery system (K0730) and Iloprost (Q4074)

- Medical records support the delivery of treprostinil (J7686) or iloprost (Q4074) to beneficiaries who meet the following criteria (See LCD for ICD codes):
  - Beneficiary has a diagnosis of pulmonary artery hypertension; and
  - Pulmonary hypertension is not secondary to pulmonary venous hypertension or disorders of the respiratory system; and
  - Beneficiary has primary pulmonary hypertension or pulmonary hypertension which is secondary to one (1) of the following conditions:
    - Connective tissue disease; or
    - Thromboembolic disease of the pulmonary arteries; or
    - HIV infection; or
    - Cirrhosis; or
    - Anorexigens (diet drugs); or
    - Congenital left to right shunts; and

- If one (1) of the above conditions is present, the following must also be met:
  - Pulmonary hypertension has progressed despite maximal medical and/or surgical treatment of the identified condition; and
  - Mean pulmonary artery pressure is > 25 mm Hg at rest or > 30 mm Hg with exertion; and
  - Beneficiary has significant symptoms from the pulmonary hypertension (i.e., severe dyspnea on exertion, and either fatigability, angina, or syncope); and
  - Treatment with oral calcium channel blocking agents has been tried and failed, or has been considered and ruled out.